Lidocaine enhances antitumor effects of sorafenib and GW5074 in colorectal cancer cells

Targeted therapies have broadened the treatment landscape for colorectal cancer (CRC), highlighting the need for rational combination strategies. Although sorafenib and GW5074 show therapeutic promise and lidocaine may sensitise cancer cells to treatment, the mechanisms underlying these combinations...

Descripción completa

Detalles Bibliográficos

Autores principales:	Tzu-Chiao Lin, Zih-Syuan Wu, Shih-Ming Huang, Che-Wei Liu, Je-Ming Hu, Chia-Cheng Wen
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Taylor & Francis Group 2026-12-01
Colección:	Journal of Enzyme Inhibition and Medicinal Chemistry
Materias:	Lidocaine sorafenib GW5074 colorectal cancer combination index
Acceso en línea:	https://www.tandfonline.com/doi/10.1080/14756366.2026.2678755
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!